Department of Surgical Oncology, NKI-AVL, Amsterdam, The Netherlands.
Department of Radiology, Policlinico San Donato, Milan, Italy.
Ann Surg Oncol. 2021 Nov;28(12):7383-7394. doi: 10.1245/s10434-021-09865-4. Epub 2021 May 12.
Many cT3 breast cancer patients are treated with mastectomy, regardless of response to neoadjuvant systemic therapy (NST). We evaluated local control of cT3 patients undergoing breast-conserving therapy (BCT) based on magnetic resonance imaging (MRI) evaluation post-NST. In addition, we analyzed predictive characteristics for positive margins after breast-conserving surgery (BCS).
All cT3 breast cancer patients who underwent BCS after NST between 2002 and 2015 at the Netherlands Cancer Institute were included. Local recurrence-free interval (LRFI) was estimated using the Kaplan-Meier method, and predictors for positive margins were analyzed using univariable analysis and multivariable logistic regression.
Of 114 patients undergoing BCS post-NST, 75 had negative margins, 16 had focally positive margins, and 23 had positive margins. Of those with (focally) positive margins, 12 underwent radiotherapy, 6 underwent re-excision, and 21 underwent mastectomy. Finally, 93/114 patients were treated with BCT (82%), with an LRFI of 95.9% (95% confidence interval [CI] 91.5-100%) after a median follow-up of 7 years. Predictors for positive margins in univariable analysis were hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) subtype, lobular carcinoma, and non-mass enhancement (NME) on pre-NST MRI. MRI response was not correlated to positive margins. In multivariable regression, the odds of positive margins were decreased in patients with HER2-positive (HER2+; odds ratio [OR] 0.27, 95% CI 0.10-0.73; p = 0.01) and TN tumors (OR 0.17, 95% CI 0.03-0.82; p = 0.028). A trend toward positive margins was observed in patients with NME (OR 2.38, 95% CI 0.98-5.77; p = 0.055).
BCT could be performed in 82% of cT3 patients in whom BCT appeared feasible on post-NST MRI. Local control in these patients was excellent. In those patients with HR+/HER2- tumors, NME on MRI, or invasive lobular carcinoma, the risk of positive margins should be considered preoperatively.
许多 cT3 期乳腺癌患者接受了乳房切除术治疗,而不论其对新辅助全身治疗(NST)的反应如何。我们评估了 cT3 期患者在接受 NST 后行保乳治疗(BCT)的局部控制情况,评估方法基于 NST 后磁共振成像(MRI)的评估。此外,我们还分析了保乳手术后(BCS)切缘阳性的预测特征。
荷兰癌症研究所于 2002 年至 2015 年间,纳入所有接受 NST 后行 BCS 的 cT3 期乳腺癌患者。采用 Kaplan-Meier 法估计局部无复发生存期(LRFI),并采用单变量分析和多变量逻辑回归分析预测切缘阳性的特征。
在 114 例接受 NST 后行 BCS 的患者中,75 例切缘阴性,16 例局灶性切缘阳性,23 例切缘阳性。在(局灶性)切缘阳性的患者中,12 例接受了放疗,6 例接受了再次切除术,21 例接受了乳房切除术。最终,114 例患者中有 93 例(82%)接受了 BCT 治疗,中位随访 7 年后,LRFI 为 95.9%(95%置信区间[CI]为 91.5%-100%)。单变量分析显示,激素受体阳性/人表皮生长因子受体 2 阴性(HR+/HER2-)亚型、小叶癌和术前 MRI 上的非肿块强化(NME)是切缘阳性的预测因素。MRI 反应与切缘阳性无关。多变量回归分析显示,HER2 阳性(HER2+;比值比[OR]为 0.27,95%CI 为 0.10-0.73;p=0.01)和 TN 型肿瘤(OR 为 0.17,95%CI 为 0.03-0.82;p=0.028)患者切缘阳性的可能性降低。NME 患者切缘阳性的风险呈阳性趋势(OR 为 2.38,95%CI 为 0.98-5.77;p=0.055)。
在 NST 后 MRI 上可行 BCT 的 cT3 期患者中,82%可接受 BCT 治疗。这些患者的局部控制情况非常好。对于 HR+/HER2-肿瘤、MRI 上的 NME 或浸润性小叶癌患者,术前应考虑切缘阳性的风险。